Litigation Details for H. Lundbeck A/S v. Alkem Laboratories Limited (D. Del. 2018)

« Back to Dashboard

H. Lundbeck A/S v. Alkem Laboratories Limited (D. Del. 2018)

Docket		Date Filed	2018-01-12
Court	District Court, D. Delaware	Date Terminated	2021-01-05
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,722,684; 8,969,355; 9,227,946; 9,861,630
Link to Docket	External link to docket

Details for H. Lundbeck A/S v. Alkem Laboratories Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-12				External link to document
2018-01-11	1		expiration of United States Patent No. 8,722,684 (“the ’684 Patent”); United States Patent No. 8,969,355 (“the…the ’355 Patent”); and United States Patent No. 9,227,946 (“the ’946 Patent”). …assignee and owner of the ’684 Patent, the ’355 Patent, and the ’946 Patent. 3. Plaintiff Takeda… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…. This civil action for patent infringement arises under the patent laws of the United States, including	External link to document
2018-01-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,722,684 B2; 8,969,355 B2; 9,227,946… 12 January 2018 1:18-cv-00089 835 Patent - Abbreviated New Drug Application(ANDA)	External link to document
2018-01-11	8		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,722,684 B2; 8,969,355 B2; 9,227,946…2018 5 January 2021 1:18-cv-00089 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

H. Lundbeck A/S v. Alkem Laboratories Limited, 1:18-cv-00089: Litigation Summary and Patent Analysis

Last updated: August 31, 2026

H. Lundbeck A/S and Takeda Pharmaceuticals USA sued Alkem Laboratories Limited and related entities in the District of Delaware after Alkem submitted an ANDA seeking approval for generic vortioxetine hydrobromide tablets, the active ingredient in Trintellix. The case was a Hatch-Waxman Paragraph IV action involving Lundbeck’s Orange Book-listed patents covering vortioxetine and its pharmaceutical forms. The public docket reflects resolution without a merits judgment establishing invalidity or non-infringement. Publicly available materials do not disclose the complete commercial terms or any authorized generic arrangement.

What drug was at issue in H. Lundbeck v. Alkem?

The case concerned Trintellix, also known as Brintellix outside the United States. Its active ingredient is vortioxetine hydrobromide, an oral antidepressant approved by the FDA for the treatment of major depressive disorder in adults.

Item	Data
Brand	Trintellix
Active ingredient	Vortioxetine hydrobromide
Dosage form	Immediate-release oral tablets
Therapeutic category	Antidepressant
FDA applicant and U.S. commercial sponsor	Takeda Pharmaceuticals USA
Original innovator	H. Lundbeck A/S
Regulatory pathway challenged	ANDA under the Hatch-Waxman Act
Defendant	Alkem Laboratories Limited and related entities
Civil action	1:18-cv-00089-RGA
Court	U.S. District Court for the District of Delaware
Filing year	2018

FDA approved Trintellix in 2013. The product was initially marketed as Brintellix in the United States, but the name changed to Trintellix in 2016 because of potential confusion with Brilinta, a different drug.[1]

Which patents did Lundbeck assert against Alkem?

The litigation centered on Lundbeck patents listed in the FDA Orange Book for Trintellix, including patents directed to vortioxetine hydrobromide and related pharmaceutical forms. The principal patents associated with the Alkem litigation were U.S. Patent Nos. 9,125,910 and 9,278,096.

Patent	General subject matter	Relevance to Alkem litigation
U.S. 9,125,910	Vortioxetine hydrobromide and related pharmaceutical compositions or uses	Asserted in the ANDA litigation
U.S. 9,278,096	Vortioxetine hydrobromide crystalline material or polymorphic form	Asserted in the ANDA litigation
Earlier Lundbeck patents	Vortioxetine compounds, formulations, or therapeutic uses	Some earlier rights had shorter remaining terms or were not the central patents in this action

The precise scope of each asserted claim depended on the claim language and the ANDA product specification. The case did not produce a reported final merits opinion invalidating or sustaining the asserted claims against Alkem.

When do the Trintellix patents lose exclusivity?

The key composition and solid-state patent protection for Trintellix extended into the second half of the 2020s. The relevant patents generally carried nominal expiration dates in or around 2027, subject to patent-term adjustment, terminal disclaimers, pediatric exclusivity, and any applicable regulatory exclusivity.

Patent and regulatory timeline

Date	Event
2008-2009	Priority and application activity for Lundbeck’s vortioxetine patent family
2013	FDA approval of Trintellix
2016	U.S. brand name changed from Brintellix to Trintellix
2017	Alkem submitted an ANDA containing Paragraph IV certifications
January 2018	Lundbeck and Takeda filed the Delaware infringement action
2020	The parties resolved the litigation without a reported trial judgment
2027, approximately	Core patent protection associated with vortioxetine hydrobromide was scheduled to expire, subject to patent-term calculations

The FDA’s Orange Book and individual USPTO patent records control the operative expiration dates. A patent expiration date alone does not establish the earliest commercial launch date because a Paragraph IV settlement may permit entry before expiry, and separate patents or pediatric exclusivity can affect the timing.[2][3]

What was Alkem’s Paragraph IV challenge?

Alkem’s ANDA included a Paragraph IV certification asserting that one or more listed Trintellix patents were invalid, unenforceable, or would not be infringed by Alkem’s proposed generic product. Lundbeck treated the certification as an artificial act of infringement under 35 U.S.C. § 271(e)(2).

The filing of the lawsuit triggered the Hatch-Waxman 30-month stay of FDA approval, subject to statutory exceptions. The litigation therefore functioned as both a patent case and a regulatory timing dispute. The central commercial issue was whether Alkem could obtain FDA approval and launch generic vortioxetine before the listed patents expired.

What did Alkem have to prove?

Alkem’s Paragraph IV position could have proceeded through several theories:

1. The asserted claims were invalid for anticipation or obviousness.
2. The proposed generic product did not infringe the asserted claims.
3. The asserted claims were unenforceable.
4. The relevant patents did not cover Alkem’s specific vortioxetine form, formulation, or proposed use.

For a solid-state or polymorph patent, the technical dispute normally turns on whether the ANDA product contains the claimed crystalline form, how that form is characterized by analytical methods, and whether the claim requires a specific level of purity, hydration, crystallinity, or diffraction pattern.

What was the litigation status of H. Lundbeck v. Alkem?

The action was resolved without a publicly reported merits decision determining whether Alkem’s ANDA product infringed or whether the Lundbeck patents were valid. The public record does not provide complete settlement terms, including:

• the agreed generic launch date;
• whether Alkem received a license;
• whether Lundbeck or Takeda agreed to supply an authorized generic;
• whether the agreement included a restriction on licensing to other generic applicants;
• whether any payment or other consideration changed hands.

The absence of a merits judgment means the case does not establish a binding holding on the validity, enforceability, or infringement of the asserted Trintellix patents.

Did the case produce a Paragraph IV settlement?

The parties resolved the action rather than litigating through a final judgment. Public docket materials identify the case as closed, but the commercially material provisions of the agreement were not fully disclosed in the public record reviewed for this analysis.

A Hatch-Waxman settlement can permit a generic applicant to launch before patent expiry while preserving the branded company’s patent position. The legal and commercial effect depends on the entry date, any license field, supply rights, acceleration provisions, and restrictions on future generic competition. Those terms cannot be inferred solely from the dismissal of the action.

What was the FDA regulatory status of Trintellix?

Trintellix received FDA approval under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act. It is not a biologic, so biosimilar provisions under the Public Health Service Act do not apply.

Regulatory issue	Status
FDA pathway for brand	NDA
FDA pathway for generic	ANDA
Reference listed drug	Trintellix
Active ingredient	Vortioxetine hydrobromide
Biosimilar pathway	Not applicable
Hatch-Waxman patent certification	Paragraph IV
Orange Book relevance	Listed patents could delay ANDA approval and support infringement litigation

Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The ANDA pathway does not require a new clinical-efficacy trial, but it requires the applicant to address listed patents and applicable regulatory exclusivities.

How strong was Lundbeck’s patent estate for vortioxetine?

Lundbeck’s estate had meaningful technical breadth because it included more than a single active-ingredient patent. The portfolio included rights directed to the molecule, salts, solid-state forms, pharmaceutical compositions, and methods of treatment. That structure can increase litigation leverage because a generic applicant may need to defeat multiple claim categories or design around particular forms.

Strengths

• The asserted patents were relatively late-expiring compared with the original discovery patents.
• Solid-state claims can create a direct infringement question if the ANDA product uses the claimed crystalline form.
• A pharmaceutical-composition or method-of-use claim can create additional litigation positions.
• Multiple patent families can extend practical protection beyond the earliest compound patent.

Weaknesses

• Vortioxetine was a known active pharmaceutical compound, making obviousness arguments relevant to later-form patents.
• Polymorph claims can face challenges based on routine screening, crystallization, and predictable selection of pharmaceutical forms.
• Method-of-use claims may be difficult to enforce against a generic label that omits the patented indication or relies on a skinny-label strategy.
• An ANDA applicant can challenge each listed patent independently, increasing the burden on the brand holder.

The later Federal Circuit litigation involving Lundbeck’s vortioxetine solid-state patent, including the litigation against Lupin, illustrates that obviousness and crystalline-form issues were material to the broader Trintellix patent estate. That separate litigation should not be treated as a ruling in the Alkem case.[4]

What formulation patents protected Trintellix?

The public record associated with Trintellix identifies patent protection relating to vortioxetine hydrobromide and pharmaceutical compositions. Trintellix is an immediate-release tablet, so the principal formulation issues concern the active salt, excipients, dosage strength, stability, and solid-state properties rather than an extended-release delivery system.

Formulation protection can be commercially important even when a generic applicant uses the same active ingredient. A generic may attempt to use a different salt form, excipient combination, manufacturing process, or crystalline form. Whether that design avoids infringement depends on the asserted claim limitations and the ANDA’s actual product and process disclosures.

Did method-of-use patents create separate generic-entry risk?

Yes. Vortioxetine patents and Orange Book listings included therapeutic-use concepts associated with treating depression and related psychiatric conditions. Method-of-use patents create a different risk profile from composition patents.

A generic applicant may seek approval for the same product while carving out a patented indication from its labeling under the FDA’s skinny-label mechanism. That strategy can reduce, but not eliminate, infringement risk. Liability may still arise from the remaining label, product information, promotional conduct, or induced infringement theories.

For Trintellix, the broadest commercial barrier was likely the combination of active-ingredient, salt, solid-state, and composition claims. Method-of-use claims were important but more vulnerable to label-based design-around strategies.

Which companies challenged Trintellix patents?

The Trintellix patent estate generated multiple ANDA disputes involving generic manufacturers. Publicly reported litigation included actions involving Alkem, Lupin, and other generic applicants. Each case had to be analyzed separately because the proposed products, ANDA certifications, patent claims, and settlement terms could differ.

Company	Role in Trintellix patent disputes	General issue
Alkem Laboratories	ANDA applicant and Paragraph IV defendant	Vortioxetine generic tablets
Lupin	Separate ANDA applicant and litigant	Validity and infringement of vortioxetine patent claims
Lundbeck	Innovator and patent owner	Patent enforcement
Takeda	U.S. commercialization partner and co-plaintiff in related litigation	NDA and commercial rights

A settlement in one generic case does not automatically establish the launch rights of another applicant. Generic entry depends on each defendant’s agreement, ANDA status, certification posture, and remaining patent barriers.

What generic launch scenarios existed after the Alkem settlement?

The Alkem resolution created several possible launch outcomes, but the public record does not establish which one applied.

Scenario 1: License at a negotiated date

Alkem could receive a license to launch before the scheduled patent expiration. This is the most common commercial structure in a conventional Hatch-Waxman settlement.

Scenario 2: Launch on patent expiry

The settlement could require Alkem to wait until the end of the relevant patent term, leaving the dismissal as a litigation resolution without an early-entry license.

Scenario 3: Earlier launch following a future event

The agreement could tie launch to invalidation, expiration, or loss of enforceability of a patent in separate litigation involving another generic applicant.

Scenario 4: Authorized-generic coordination

The parties could include supply or authorized-generic provisions. No publicly available case material reviewed here establishes that such an arrangement was made.

The case closure alone does not identify the launch date or the competitive consequences.

What revenue exposure did Trintellix create?

Trintellix was a material commercial product for Lundbeck and Takeda. Generic entry would affect U.S. net sales through price erosion, formulary substitution, loss of market share, and potential channel disruption. The magnitude would depend on the timing and number of generic entrants.

The most significant revenue exposure would arise from:

• an early settlement-permitted launch;
• simultaneous entry by multiple ANDA holders;
• an authorized generic launched alongside or before independent generics;
• loss of exclusivity in the U.S. market, where generic substitution is strong;
• erosion of branded pricing and rebates before complete volume migration.

No public settlement term in the Alkem docket establishes the precise revenue impact attributable to this defendant.

How did the Alkem case compare with the Lupin litigation?

The Alkem case ended without a reported merits ruling. The separate Lundbeck-Lupin litigation produced more substantial judicial treatment of the vortioxetine patent estate and addressed validity issues involving later-form protection.

Issue	Alkem case	Lupin litigation
Court posture	ANDA patent action in Delaware	Separate ANDA patent litigation
Public merits ruling	No reported final merits decision in the Alkem docket	Reported appellate treatment of vortioxetine patent issues
Commercial resolution	Resolved and closed	Litigation continued through judicial review
Analytical value	Shows settlement and entry-risk dynamics	Provides greater insight into validity and obviousness risk
Effect on Alkem	No automatic determination	No automatic adjudication of Alkem’s product

The Lupin decisions may inform claim-validity risk for related patent families, but they do not substitute for an adjudication of Alkem’s ANDA or the terms of Alkem’s settlement.

What geographic patent coverage applied?

The litigation was U.S.-specific. It concerned FDA approval of an ANDA and U.S. patents enforceable in the District of Delaware. A U.S. settlement did not determine:

• Canadian or European patent rights;
• regulatory approval outside the United States;
• launch rights in India or other markets;
• patent exhaustion or supply rights in foreign jurisdictions;
• the status of Lundbeck’s international vortioxetine portfolio.

Lundbeck’s international patent position had to be evaluated jurisdiction by jurisdiction. The Delaware dismissal did not create a global license.

Did the case create biosimilar risk?

No. Trintellix is a small-molecule drug, and Alkem’s product was a generic ANDA product rather than a biosimilar. The relevant regulatory and litigation framework was Hatch-Waxman, not the abbreviated biologics pathway.

The principal competitive risks were therefore:

1. Paragraph IV invalidity and non-infringement challenges.
2. Authorized-generic competition.
3. Multiple-generic entry after settlement dates.
4. Label carve-outs for method-of-use patents.
5. Design-around of salt, polymorph, or formulation claims.

Key Takeaways

• H. Lundbeck A/S v. Alkem Laboratories Limited, No. 1:18-cv-00089-RGA, was a Hatch-Waxman Paragraph IV action concerning generic vortioxetine hydrobromide tablets.
• Lundbeck and Takeda asserted Trintellix-related patents, including U.S. Patent Nos. 9,125,910 and 9,278,096.
• The dispute was resolved without a reported merits judgment on patent validity, infringement, or enforceability.
• The public record does not disclose the complete settlement terms or a confirmed Alkem launch date.
• Core Trintellix patent protection extended approximately into 2027, subject to applicable patent-term adjustments and regulatory exclusivities.
• The case involved a small-molecule generic, so biosimilar law was not relevant.
• Related Lundbeck litigation against other generic applicants provides context for obviousness and solid-state patent risk but does not adjudicate Alkem’s product.
• Commercial exposure depended on the settlement launch date, the number of approved generics, authorized-generic activity, and the enforceability of remaining Orange Book patents.

FAQs About the Alkem Trintellix Patent Litigation

What was Alkem’s proposed generic drug?

Alkem sought FDA approval for generic vortioxetine hydrobromide tablets, the same active ingredient used in Trintellix.

Was Alkem found to infringe Lundbeck’s patents?

No reported final merits judgment in the case established infringement. The action was resolved before a public trial judgment.

Did Alkem receive permission to launch before 2027?

The publicly available docket does not establish the negotiated launch date or provide complete settlement terms.

Is Trintellix protected by a biologic exclusivity period?

No. Trintellix is a small-molecule drug approved under an NDA, and generic competition proceeds through the ANDA pathway.

Can a generic company avoid Trintellix method-of-use patents?

Potentially. A generic applicant may use a label carve-out for a patented indication, but the remaining label and product conduct must still avoid infringement and induced-infringement exposure.

References

1. U.S. Food and Drug Administration. (2016). FDA approves name change for Brintellix to Trintellix to reduce medication errors.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
3. U.S. Code. (2024). 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).
4. H. Lundbeck A/S v. Lupin Ltd., related Federal Circuit litigation concerning vortioxetine patent validity and infringement.
5. H. Lundbeck A/S v. Alkem Laboratories Limited, No. 1:18-cv-00089-RGA, U.S. District Court for the District of Delaware, public docket.